These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Prevalence and antibacterial resistance patterns of extended-spectrum beta-lactamase producing Gram-negative bacteria isolated from ocular infections. Rameshkumar G; Ramakrishnan R; Shivkumar C; Meenakshi R; Anitha V; Venugopal Reddy YC; Maneksha V Indian J Ophthalmol; 2016 Apr; 64(4):303-11. PubMed ID: 27221683 [TBL] [Abstract][Full Text] [Related]
28. Antimicrobial susceptibility and extended-spectrum beta-lactamase rates in aerobic gram-negative bacteria causing intra-abdominal infections in Vietnam: report from the Study for Monitoring Antimicrobial Resistance Trends (SMART 2009-2011). Biedenbach DJ; Bouchillon SK; Hoban DJ; Hackel M; Phuong DM; Nga TT; Phuong NT; Phuong TT; Badal RE Diagn Microbiol Infect Dis; 2014 Aug; 79(4):463-7. PubMed ID: 24923210 [TBL] [Abstract][Full Text] [Related]
29. Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms. Kois AK; Nicolau DP; Kuti JL Curr Opin Infect Dis; 2020 Dec; 33(6):482-494. PubMed ID: 33009141 [TBL] [Abstract][Full Text] [Related]
30. Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections. Suárez CJ; Lolans K; Villegas MV; Quinn JP Expert Rev Anti Infect Ther; 2005 Dec; 3(6):915-22. PubMed ID: 16307504 [TBL] [Abstract][Full Text] [Related]
31. Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options. Jean SS; Lee WS; Lam C; Hsu CW; Chen RJ; Hsueh PR Future Microbiol; 2015; 10(3):407-25. PubMed ID: 25812463 [TBL] [Abstract][Full Text] [Related]
32. Dual beta-lactam therapy for serious Gram-negative infections: is it time to revisit? Rahme C; Butterfield JM; Nicasio AM; Lodise TP Diagn Microbiol Infect Dis; 2014 Dec; 80(4):239-59. PubMed ID: 25308565 [TBL] [Abstract][Full Text] [Related]
33. Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms. Schuetz AN; Reyes S; Tamma PD J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29237787 [TBL] [Abstract][Full Text] [Related]
34. Antimicrobial-resistant Gram-negative infections in neonates: burden of disease and challenges in treatment. Folgori L; Bielicki J; Heath PT; Sharland M Curr Opin Infect Dis; 2017 Jun; 30(3):281-288. PubMed ID: 28306563 [TBL] [Abstract][Full Text] [Related]
35. beta-Lactamases of increasing clinical importance. Bush K Curr Pharm Des; 1999 Nov; 5(11):839-45. PubMed ID: 10539991 [TBL] [Abstract][Full Text] [Related]
36. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Zowawi HM; Harris PN; Roberts MJ; Tambyah PA; Schembri MA; Pezzani MD; Williamson DA; Paterson DL Nat Rev Urol; 2015 Oct; 12(10):570-84. PubMed ID: 26334085 [TBL] [Abstract][Full Text] [Related]
37. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Tang SS; Apisarnthanarak A; Hsu LY Adv Drug Deliv Rev; 2014 Nov; 78():3-13. PubMed ID: 25134490 [TBL] [Abstract][Full Text] [Related]
38. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. Falcone M; Paterson D J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599 [TBL] [Abstract][Full Text] [Related]
39. An update on β-lactamase inhibitor discovery and development. Docquier JD; Mangani S Drug Resist Updat; 2018 Jan; 36():13-29. PubMed ID: 29499835 [TBL] [Abstract][Full Text] [Related]
40. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria. Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]